The clinical diagnosis of Parkinson s disease rests on

Size: px
Start display at page:

Download "The clinical diagnosis of Parkinson s disease rests on"

Transcription

1 ORIGINAL ARTICLE - NEUROLOGY Non motor symptoms of Parkinson s Diseaseits prevalence across the various stages of Parkinson s disease and its correlation with the severity and duration of the disease Chandrasekaran P (1), Mugundhan K (2) Abstract Background: The non classical features of Parkinson s disease like nonmotor symptoms are often poorly recognized but dominate the clinical picture of advanced Parkinson s disease and contribute to severe disability, impaired quality of life, and shortened life expectancy. Aim: To study the prevalence of nonmotor features across the various stages of Parkinson s disease and to correlate it with the severity and duration of the disease. Methods: 50 Patients with Idiopathic Parkinson s disease who attended the Neurology outpatient clinic and was inpatients at Neuromedicine ward at GOVT RAJAJI HOSPITAL, MADURAI were enrolled and underwent a detailed and complete neurological examination. The motor symptoms were assessed through the Unified Parkinson s Disease Rating Scale (UPDRS) and the disease staged according to the Hoehn and Yahr staging from stage 0 to stage 5.The nonmotor features were assessed through the Nonmotor Symptoms Questionnaire (NMS QUEST) which contains 30 items. CT AND MRI brain was done to exclude Parkinson plus syndrome, vascular Parkinsonism and secondary Parkinsonism. Results: Non motor symptoms were prevalent across all stage of Parkinson s disease. The most prevalent ones were autonomic which includes constipation, urgency, orthostatic hypotension, erectile dysfunction, and drooling and the most prevalent neurobehavioral abnormalities were depression, fatigue, recent memory loss, and anxiety. The number of NMS increased as the disease severity progressed. The number of NMS in stages 1 and 1.5 were the least. It increased through stages 2 and 2.5 and was highest reported in stages 3 and 4. Conclusions: The early recognition of these non motor symptoms may well perhaps lead to an earlier diagnosis of Parkinson s disease and treatment of NMS may go long way in improving the quality of PD patients as well as the economic burden on the care givers. Key words: Non motor symptoms, Parkinson s disease, Nonmotor symptom questionnaire. Introduction The clinical diagnosis of Parkinson s disease rests on the identification of the characteristics related to dopamine deficiency that are a consequence of degeneration of the substantia nigra pars compacta.1 However, non dopaminergic and nonmotor symptoms are sometimes present before diagnosis and almost inevitably emerge with disease progression. Indeed, non motor symptoms dominate the clinical picture of advanced Parkinson s disease and contribute to severe disability, impaired quality of life, and shortened life expectancy.2-4 By contrast with dopaminergic symptoms of the disease, for which treatment is available, nonmotor symptoms are often poorly recognised and inadequately treated.3 However, attention is now being focused on the recognition and quantization of non motor symptoms which will form the basis of improved treatments. The nonmotor symptoms include neuro behavioural and cognitive symptoms, sleep disorders, autonomic symptoms, sensory symptoms and miscellaneous symptoms like diplopia, fatigue and seborrhoea, hair loss, leg edema.5 The nonmotor symptoms questionnaire (NMS Questionnaire) and the nonmotor symptom scale (NMSS) were developed to assess the frequency and severity of nonmotor symptoms in Parkinson s patients across all stages.3 The nonmotor symptoms Questionnaire was validated in March 2007 by the Movement Disorder Society. It covers 9 domains and includes 30 items, including sleep / fatigue, cardiovascular, mood/cognition, perceptual problems, attention / memory, gastrointestinal, urinary, sexual functions and miscellaneous. The nonmotor symptoms Questionnaire does not provide an overall score or disability and is not a graded rating instrument. It is a screening tool designed to draw attention to the presence of nonmotor symptoms and to initiate further investigation. Recent studies using the Nonmotor Symptoms Quest for Parkinson s patients have highlighted the significant occurrence of a range of different nonmotor symptoms in PD patients. Further studies validating the nonmotor symptom scale (NMSS) also indicated a strong relationship between the burden of nonmotor symptoms in Parkinson s disease and health related quality of life (QOL). The development of tools such as the Nonmotor Symptoms Please Scan this QR Code to View this Article Online Article ID: 2017:04:03:03 Corresponding Author: Mugundhan K mugundhan69@gmail.com 13 1, Department of Neurology,Govt. Mohan Kumaramangalam Medical College Hospital, Salem, Affiliated to Tamilnadu Dr.MGR Medical University 2,, Department of Neurology,Govt. Stanley Medical College Hospital, Salem, Affiliated to Tamilnadu Dr.MGR Medical University

2 14 Quest and Nonmotor Symptoms Scale alongside the re vamped Unified Parkinson s Disease Rating Scale which includes a specific nonmotor domain will help define research and therapy to improve the recognition and management of nonmotor symptoms of Parkinson s disease.6 Some nonmotor symptoms, including depression, constipation, pain, genitourinary problems, and sleep disorders, can be improved with available treatments. Other non motor symptoms can be more refractory and need the introduction of novel non dopaminergic drugs. Inevitably, the development of treatments that can slow or prevent the progression of Parkinson s disease and its multicentric neurodegeneration provides the best hope of curing nonmotor symptoms. Methodology This is a cross sectional descriptive study involving 50 patients with Idiopathic Parkinson s disease who attended the Neurology outpatient clinic and who were inpatients at Neuro medicine ward at GOVT RAJAJI HOSPITAL, MAD- URAI were studied. A detailed and complete neurological examination was done. The motor symptoms were assessed through the Unified Parkinson s Disease Rating Scale (UP- DRS) and the disease staged according to the Hoehn and Yahr staging from stage 0 to stage 5.7 The nonmotor features were assessed through the Nonmotor Symptoms Questionnaire (NMS QUEST) which contains 30 items. This included cognitive dysfunction, depression, sleep disorders, fatigue, sensory and autonomic abnormalities. CT AND MRI brain was done to exclude Parkinson plus syndrome, vascular Parkinsonism and secondary Parkinsonism. The prevalence of these Non motor symptoms across the various stages of the disease was studied and its correlation with the disease severity and duration assessed. Adult patients with idiopathic Parkinson s disease were included. Parkinson s Plus Syndromes like Progressive Supranuclear Palsy (PSP), Multi System Atrophy (MSA), and Corticobasal Degeneration (CBD), diffuse lewy body dementia (DLBD), patients with Vascular Parkinsonism, secondary Parkinsonism, Young onset Parkinson s disease were excluded. Results This study included 50 patients with Idiopathic Parkinson s Disease and the baseline characteristics of these patients are shown in table 1-4 and the analysis of nonmotor symptoms of Parkinson s disease is shown in table 5-8. Table.1 - Demographic profile of the patients Characteristic sex Male Female Age distribution in years Duration of disease < 5 years years > 10 years 3 6 Table.2 - Drug history of the patients Drug prescribed Dopamine precursors Anticholinergics Dopamine agonist 4 8 COMT inhibitors 1 2 Antidepressants 6 12 Anxiolytics 2 4 Laxatives 4 8 MAO-B inhibitors 1 2 Table 3 - Family History And Co-Morbidities Of The Patients Family history Positive PD 3 6 Negative PD Co-morbidities Smoker 4 8 Alcoholic 6 12 Hypertension 4 8 Diabetes 4 8 IHD 1 2 No Comorbid conditions Discussion: The present study when compared to Chaudhari et al showed similarly high prevalence of the following non motor symptoms namely depression, constipation, sleep,

3 taste and smell disturbances. The next prevalent NMS were sexual disturbances, urinary urgency, memory loss, cramps in legs, anxiety and fatigue which were less when compared to Chaudhari et al. 3 Hallucinations, weight loss and dreams were least prevalent when compared to Chaudhari et al. The most prevalent NMS were autonomic symptoms namely constipation, urgency, orthostatic hypotension, sexual dysfunction, swallowing difficulties, sweating disturbances and sialorrhea. Table 4: Hoehn and Yahr Staging of the patients Hoehn and Yahr Staging Stage Stage Stage Stage Stage Stage The analysis of nonmotor symptoms of Parkinson s disease Autonomic features Table 5: Enumeration of autonomic features of the patients Orthostatic hypotension 8 16 Sweating dysfunction Hypohydrosis 3 6 Hyperhydrosis 3 6 Urologic symptoms Urgency Precipitancy 1 2 Hesitancy 2 4 Sexual impotence Erectile dysfunction 8 16 Premature ejaculation 3 6 GIT symptoms Sialorrhea 5 10 Decreased salivation 2 4 Reflex esophagitis 7 14 Constipation Weight loss 1 2 Dermatological features Seborrhea 1 2 Hair loss 1 2 Table 6: Enumeration of Neurobehavioral and Cognitive Abnormalities of the patients Neurobehavioral and Cognitive Abnormalities Anxiety 5 10 Fatigue 7 14 Akathisia 2 4 Depression Memory loss 8 16 Auditory hallucinations 3 6 Excessive eating 3 6 Euphoria 2 4 Hyper sexuality 1 2 Aggression 2 4 Phobias 1 2 Addictive personal 2 4 Table 7: Enumeration of Sleep disorders of the patients Sleep disorders Excessive day drowsiness 6 12 REM sleep behavior Cramps in the legs Vivid dreams 3 6 Table 8: Enumeration of Sensory abnormalities of the Sensory abnormalities patients Parathesia 5 10 Anosmia 5 10 Hyposmia 8 16 Others 4 8 Autonomic symptoms study in Parkinson s disease by D.Verbaan et.al, studied 420 patients with Parkinson s disease found gastro intestinal, urinary symptoms are common with increasing age, disease severity and with higher doses of dopaminergic medications.8 The present study when compared to D.Verbaan et al study showed constipation, swallowing difficulties, other gastro intestinal symptoms were common in stage 2.5, stage 3 and in patients aged more than 60 years. Urinary symptoms like urgency were common in stages 2, 2.5, 3and in patients aged more than 50 years. Next common NMS in the present study were Neuropsychiatric symptoms like depression, memory disturbances, anxiety and hallucinations followed by sleep disturbances which include insomnia, sleepiness, cramps in legs, REM sleep behaviour disorder and dreams. Fatigue and weight loss, seborrhoea, hair loss, addictive behaviour, aggression, 15

4 16 decreased sweating were reported in a small of patients. Lisa M.Shulman, MD, et al, studied co-morbidity of NMS and their relation to Parkinson s disease severity in 118 patients. Depression, anxiety, fatigue, sleep disturbances, sensory symptoms. Increased co-morbidity of the five or more non motor symptoms was associated with greater PD severity.9 The present study showed depression, sleep disturbances, sensory disturbances which are almost same with M.Shulman et al study. Anxiety and fatigue were less compared with above study. And more NMS symptoms occurred in HOEHN YAHR stage 2.5,3 and 4. The number of NMS ranged between 3 to 4 in stage 1, 4to 9 in stage 1.5, 3 to 13 in stage 2, 7 to 21 in stage 2.5, and finally 7 to 23 in stage 3 and 4. In the Indian context, Arindam Ghosh et al, have studied 34 patients of idiopathic PD. 10 Depression(58%), sleep disturbances such as excessive day time somnolence, insomnia (44.1%), autonomic symptoms such as constipation(76.4%), urgency(67.6%), sweating(47%), sexual dysfunction(64.7%), drooling(61.8%) were the NMS noted. NMS add to the morbidity of PD, and may even precede the onset of motor symptoms. Early identification and treatment is imperative to improve quality of life in such patients. The present study compared with above study following NMS like depression, constipation, urgency, sleep disturbances, sexual disturbances were less prevalent. The NIMS study had NMS scores between 6 to 20. The most common symptoms identified were dribbling of saliva, swallowing difficulty, urinary urgency, sexual dysfunction, unexplained pains, anxiety, dreams, insomnia, sweating disturbances, memory disturbances and falls. Alteration in taste and smell, bowel and urinary incontinence, weight loss and hallucinations were seen in fewer patients. In another study carried out at SCIMT, Thiruvananthapuram, NMS was assessed by the NMS Scale (9 domains) in 100 consecutive PD patients.11 The Mood / cognition domain was most frequently involved (84.2%), while the cardiovascular domain was the least affected (22.4%). Four of the domains namely, cardiovascular, perceptual problems- hallucinations, gastrointestinal and urinary showed significant correlation with the duration of the disease and severity of PD. There was a significant correlation between the overall severity of NMS and duration of disease and severity of PD. And NMS in PD differ from those in aging in frequency, severity, sex predilection, and domain involvement. As compared to above study the present study showed cognitive and behavioural, GIT domains were more frequently involved than cardiovascular, sensory, urinary domains and there were significant correlation between duration of disease and severity of NMS in PD patients. Manmohan Mehindiratta et al12 concluded that the NMS are universal features of idiopathic PD. They add significantly to the overall disability caused by PD and critical determinants of health related quality of life of affected patients. There was evidence that many NMS may antedate the onset of motor symptoms of PD by years or even decades. Early recognition and treatment of NMS may go long way in improving the quality of life of PD patients as well as the economic burden of carers. Deepthi Varma et al, AIMS. Delhi showed that patients with REM sleep behaviour disorder had significantly higher prevalence of insomnia, nocturnal awakening, early morning awakening and snoring.13 Most clinical events confined to limb or vocalisation. REM sleep behaviour disorder may proceed or follow PD onset.rem sleep behaviour has higher occurrence of hallucination and other nocturnal problems. The present study compared with above study, REM sleep behaviour disorder had a higher prevalence(20%), when compared with other sleep related problems. D. Verbaan et al has characterised these non motor domains in patients of the Profiling Parkinson s Disease (PROPARK) cohort and describes their relation with other domains of the disease as well as their impact on disability and quality of life. Of the domains evaluated olfaction is the only domain that seemed unrelated to any of the other impairment domains. All other nonmotor symptoms were related to symptoms of other domains. The strongest relation was found between night time sleep problems and depressive symptoms and between psychotic and autonomic symptoms. As compared with previous study, the present study showed high prevalence of sleep problems and depression and strong correlation with autonomic symptoms like urgency. The relation found between the different impairment domains may emerge through different causes. First two domains may be related because of a shared underlying mechanism that is inherent to the disease or may be induced by medication or by a combination of both. Second a relation between impairment domains may emerge because different brain regions are simultaneously affected by the disease process. The pathological staging system of Braak, in which the upper brainstem, midbrain and limbic system become involved as the disease progresses, may explain the co-occurrence of features from two different domains. Of the nonmotor domains in PD depressive symptoms and autonomic dysfunction were the most important contributors to health

5 related quality of life. Our study has also demonstrated relation between insomnia, depression and autonomic symptoms. Conclusion Non motor symptoms were prevalent across all stage of Parkinson s disease and the most prevalent were autonomic disturbances which included constipation, urgency, orthostatic hypotension, erectile dysfunction, and drooling. The most prevalent neurobehavioral abnormalities were depression, fatigue, recent memory loss, and anxiety. The number of NMS increased as the disease severity progressed and the number of NMS in stages 1 and 1.5 were the least. It increased through stages 2 and 2.5 and was highest reported in stages 3 and 4.The early recognition of these symptoms may well perhaps lead to an earlier diagnosis and treatment of NMS may go long way in improving the quality of PD patients as well as the economic burden on the care givers. bout AM, Hilten JJ van. Patient-reported autonomic symptoms in Parkinson disease. Neurology Jul 24;69(4): Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson s disease. Mov Disord May 1;16(3): Manmohan Mehndiratta, Rohit K Garg, Sanjay Pandey. Nonmotor Symptom Complex of Parkinson s Disease An Under-recognized Entity. JAPI-VOL-59, Krishnan S, Sarma G, Sarma S, Kishore A. Do nonmotor symptoms in Parkinson s disease differ from normal aging? Mov Disord Off J Mov Disord Soc Sep;26(11): Arindam Ghosh, Bhattacharya AK, Dutta A, Sengupta SB, Kumar T. Non-Motor manifestations of Parkinson s Disease- A Hospital based study. JAPI,december Vibha D, Shukla G, Goyal V, Singh S, Srivastava AK, Behari M. RBD in Parkinson s disease: a clinical case control study from North India. Clin Neurol Neurosurg Jul;113(6): References 1. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Disord Aug;4(2): Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson s disease? J Neurol Neurosurg Psychiatry Sep;69(3): Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson s disease: diagnosis and management. Lancet Neurol Mar;5(3): Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson s disease: a population-based, prospective study. J Am Geriatr Soc Aug;48(8): Poewe W. Non-motor symptoms in Parkinson s disease. Eur J Neurol Apr 1;15: Ramaker C, Marinus J, Stiggelbout AM, van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson s disease. Mov Disord Sep 1;17(5): Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord Off J Mov Disord Soc Sep;19(9): Verbaan D, Marinus J, Visser M, Rooden SM van, Stiggel- 17

Non-motor symptoms as a marker of. Michael Samuel

Non-motor symptoms as a marker of. Michael Samuel Non-motor symptoms as a marker of progression in Parkinson s s disease Michael Samuel London, UK 1 Definitions and their problems Non-motor symptoms as a marker of progression Non-motor symptoms (NMS)

More information

Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors

Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors Neurology Asia 2018; 23(4) : 327 331 Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors Kusuma Samart MD Department of Medicine, Surin Hospital, Surin Province,

More information

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential

More information

Evaluation of non-motor symptoms in Parkinson s Disease: An underestimated necessity

Evaluation of non-motor symptoms in Parkinson s Disease: An underestimated necessity HIPPOKRATIA 2013, 17, 3: 214-219 ORIGINAL ARTICLE Evaluation of non-motor symptoms in Parkinson s Disease: An underestimated necessity Bostantjopoulou S 1, Katsarou Z 2, Karakasis C 1,Peitsidou E 1, Milioni

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

Non-Motor Symptoms of Parkinson s Disease

Non-Motor Symptoms of Parkinson s Disease Non-Motor Symptoms of Parkinson s Disease Samantha Holden, MD University of Colorado Movement Disorders MOTOR SYMPTOMS Rigidity Bradykinesia Tremor Gait Imbalance NON-MOTOR SYMPTOMS Dementia Urinary frequency

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non

More information

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease 2 nd most common neurodegenerative disorder Peak age at onset is 60 years

More information

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone

More information

Optimizing Clinical Communication in Parkinson s Disease:

Optimizing Clinical Communication in Parkinson s Disease: Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of

More information

The PD You Don t See: Cognitive and Non-motor Symptoms

The PD You Don t See: Cognitive and Non-motor Symptoms The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals

More information

Evaluation of Parkinson s Patients and Primary Care Providers

Evaluation of Parkinson s Patients and Primary Care Providers Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,

More information

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline REV 3/24/09 The UCNS Geriatric Neurology examination was established to determine the level of competence

More information

Faculty. Joseph Friedman, MD

Faculty. Joseph Friedman, MD Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute

More information

The PD You Don t See: Cognitive and Non-motor Symptoms

The PD You Don t See: Cognitive and Non-motor Symptoms The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Assistant Professor of Neurology and Psychiatry University of Colorado Denver Goals 1) What are the most common non-motor

More information

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:

More information

10th Medicine Review Course st July Prakash Kumar

10th Medicine Review Course st July Prakash Kumar 10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS

More information

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE DEE SILVER M.D MOVEMENT DISORDER SPECIALIST MEDICAL DIRECTOR -- PARKINSON ASSOCIATION OF SAN DIEGO 1980 TO PRESENT SCRIPPS MEMORIAL HOSPITAL, LA JOLLA CA.

More information

The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease.

The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease. Kobe J. Med. Sci., Vol. 56, No. 5, pp. E214-E219, 2010 The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease. NAOKO YASUI 1, KENJI SEKIGUCHI 1, HIROTOSHI HAMAGUCHI 1, and FUMIO KANDA

More information

Professor K Ray Chaudhuri

Professor K Ray Chaudhuri Centre of excellence Parkinson s Care and Research The Spectrum of Non Motor Symptoms in Parkinson s Evolving concepts Professor K Ray Chaudhuri St Thomas Hospital Guy s Hospital National Parkinson Foundation

More information

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Pathways bolt 16/6/06 20:38 Page 1 Pa t h w a y s A PARADIGM FOR DISEASE MANAGEMENT IN Pa r k i n s o n s Disease MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Clinical diagnosis Pa r k i n s o n s disease

More information

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10

More information

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing

More information

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease. Sirilak yimcharoen Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically

More information

World Journal of Pharmaceutical and Life Sciences WJPLS

World Journal of Pharmaceutical and Life Sciences WJPLS wjpls, 2016, Vol. 2, Issue 6, 376-388. Research Article ISSN 2454-2229 Salma et al. WJPLS www.wjpls.org SJIF Impact Factor: 3.347 ROLE STRAIN AND BURDEN AMONG CAREGIVERS OF PARKINSON S DISEASE 1 Salma

More information

A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease

A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease Volume 12 Number 2 2009 VALUE IN HEALTH A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease Martine Visser, PhD, 1 Dagmar Verbaan, MSc, 1 Stephanie van Rooden,

More information

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:

More information

Early Clinical Features of Parkinson s Disease and Related Disorders. Dr. Alastair Noyce

Early Clinical Features of Parkinson s Disease and Related Disorders. Dr. Alastair Noyce 1 Specialist Registrar in Neurology, London Deanery Parkinson s UK Doctoral Research Fellow Project lead for PREDICT-PD Declarations Salary: Parkinson's UK, Barts and the London NHS Trust Grants: Parkinson's

More information

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

MAXIMIZING FUNCTION IN PARKINSON S DISEASE 1 MAXIMIZING FUNCTION IN PARKINSON S DISEASE September 13, 2016 End Falls This Falls Conference Jan Goldstein Elman One Step Ahead Mobility Toronto, Ontario Outline An overview of Parkinson s disease (PD):

More information

Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis

Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,

More information

Professor K Ray Chaudhuri

Professor K Ray Chaudhuri Centre of excellence Parkinson s Care and Research Guy s Hospital Professor K Ray Chaudhuri National Parkinson Foundation International Centre of Excellence and Kings College/University Hospital Lewisham

More information

Validation of the Korean-Version of the Nonmotor Symptoms Scale for Parkinson s Disease

Validation of the Korean-Version of the Nonmotor Symptoms Scale for Parkinson s Disease ORIGINAL ARTICLE J Clin Neurol 2012;8:276-283 Print ISSN 1738-6586 / On-line ISSN 2005-5013 http://dx.doi.org/10.3988/jcn.2012.8.4.276 Open Access Validation of the Korean-Version of the Nonmotor Symptoms

More information

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative Samay Jain, MD MSc Seo Young Park, PhD University of Pittsburgh Department of Neurology and Center for Research

More information

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology

More information

VEGETATIVE DISORDERS IN PARKINSON S DISEASE

VEGETATIVE DISORDERS IN PARKINSON S DISEASE VEGETATIVE DISORDERS IN PARKINSON S DISEASE LILIANA CUIBUS 1, M. PEREANU 1 PhD candidate Lucian Blaga of Sibiu, Lucian Blaga University of Sibiu Keywords: Parkinson's disease, motor symptoms, premotor

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning

More information

8/28/2017. Behind the Scenes of Parkinson s Disease

8/28/2017. Behind the Scenes of Parkinson s Disease BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic

More information

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for

More information

Behavioral Aspects of Parkinson s Disease

Behavioral Aspects of Parkinson s Disease Behavioral Aspects of Parkinson s Disease Joseph H. Friedman, MD Director, Movement Disorders Program Butler Hospital Dept of Neurology Alpert Medical School of Brown University 1 Disclosures Drugs will

More information

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even

More information

The Parkinson s You Can t See

The Parkinson s You Can t See The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?

More information

Mastering Your Anxiety in Parkinson s Disease

Mastering Your Anxiety in Parkinson s Disease Mastering Your Anxiety in Parkinson s Disease Julie Alberty, Ph.D. Krista Hanson, Ph.D. Anxiety is common in persons with Parkinson s disease Prevalence of Anxiety in PD Higher rates than the general population,

More information

Patient-reported autonomic symptoms in Parkinson

Patient-reported autonomic symptoms in Parkinson 3 Patient-reported autonomic symptoms in Parkinson disease Dagmar Verbaan 1 ; Johan Marinus 1 ; Martine Visser 1 ; Stephanie M. van Rooden 1 ; Anne M. Stiggelbout 2 ; Jacobus J. van Hilten 1 Department

More information

Parkinson s Disease Update

Parkinson s Disease Update Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms

More information

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016 Update on the DLB Module ADC Directors Meeting Baltimore, MD October 14-15, 2016 Committee Members James Galvin, Florida Atlantic University Chair James Leverenz Cleveland Clinic Brad Boeve Mayo Clinic

More information

Parkinson s Disease Current Treatment Options

Parkinson s Disease Current Treatment Options Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority

More information

Palliative Care in Adult Neurology

Palliative Care in Adult Neurology Palliative Care in Adult Neurology Veronica Bruno, MD, MPH University of Calgary, Department of Clinical Neurosciences CNSF 53 rd Congress Halifax, Nova Scotia Learning objectives 1. To understand the

More information

Patterns of motor and non-motor features in Parkinson s disease

Patterns of motor and non-motor features in Parkinson s disease Patterns of motor and non-motor features in Parkinson s disease Stephanie M Van Rooden, Martine Visser, Dagmar Verbaan, J Marinus, Bob Van Hilten To cite this version: Stephanie M Van Rooden, Martine Visser,

More information

Issues for Patient Discussion

Issues for Patient Discussion onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing

More information

Multiple choice questions: ANSWERS

Multiple choice questions: ANSWERS Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?

More information

PD ExpertBriefing: Fatigue, Sleep Disorders and Parkinson's Disease. Presented By:

PD ExpertBriefing: Fatigue, Sleep Disorders and Parkinson's Disease. Presented By: PD ExpertBriefing: Fatigue, Sleep Disorders and Parkinson's Disease Presented By: Joseph H. Friedman, M.D. Movement Disorders Program Butler Hospital Department of Neurology Alpert Medical School of Brown

More information

Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations

Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Pari Deshmukh MD Triple board-certified psychiatrist (Boards of psychiatry, addiction medicine, integrative

More information

Seyed-Mohammad Fereshtehnejad, 1,2 Örjan Skogar, 2,3 and Johan Lökk 2,4. 1. Introduction

Seyed-Mohammad Fereshtehnejad, 1,2 Örjan Skogar, 2,3 and Johan Lökk 2,4. 1. Introduction Hindawi Parkinson s Disease Volume 2017, Article ID 7802819, 8 pages https://doi.org/10.1155/2017/7802819 Research Article Evolution of Orofacial Symptoms and Disease Progression in Idiopathic Parkinson

More information

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age

More information

START THE CONVERSATION

START THE CONVERSATION START THE CONVERSATION ABOUT PARKINSON S DISEASE PSYCHOSIS Your patients with Parkinson s disease (PD) psychosis may be hesitant to report their symptoms LEARN MORE about how to identify the symptoms of

More information

Dr Barry Snow. Neurologist Auckland District Health Board

Dr Barry Snow. Neurologist Auckland District Health Board Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent

More information

Depression and Anxiety in Parkinson s Disease. Bill Collins Symposium for Parkinson s Disease 2018 Robert Underwood, Ph.D. Licensed Psychologist

Depression and Anxiety in Parkinson s Disease. Bill Collins Symposium for Parkinson s Disease 2018 Robert Underwood, Ph.D. Licensed Psychologist Depression and Anxiety in Parkinson s Disease Bill Collins Symposium for Parkinson s Disease 2018 Robert Underwood, Ph.D. Licensed Psychologist Today s Discussion Review of Parkinson s Disease and Nonmotor

More information

Is Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?

Is Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Safinamide Effective as an Add-on

More information

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials 1 Informative series of workshops featuring emerging trends in medical technology regulatory science, MDIC projects and subject matter experts sharing perspectives, progress and opportunities. Designing

More information

Alison Charleston 1 st September 2016

Alison Charleston 1 st September 2016 Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence

More information

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016 Update on the DLB Module ADC Directors Meeting Baltimore, MD October 14-15, 2016 Committee Members James Galvin, Florida Atlantic University (Chair) James Leverenz Cleveland Clinic Brad Boeve Mayo Clinic,

More information

With Time, The Pathology of PD Spreads Throughout the Brain

With Time, The Pathology of PD Spreads Throughout the Brain With Time, The Pathology of PD Spreads Throughout the Brain Braak s staging of Parkinson s disease pathology dm co sn mc hc fc 1 Hubert H. Fernandez, MD, FAAN Professor of Medicine (Neurology) Cleveland

More information

Prior Authorization with Quantity Limit Program Summary

Prior Authorization with Quantity Limit Program Summary Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.

More information

Review Article Nonmotor Symptoms in Parkinson s Disease in 2012: Relevant Clinical Aspects

Review Article Nonmotor Symptoms in Parkinson s Disease in 2012: Relevant Clinical Aspects Parkinson s Disease Volume 2012, Article ID 198316, 15 pages doi:10.1155/2012/198316 Review Article Nonmotor Symptoms in Parkinson s Disease in 2012: Relevant Clinical Aspects Anne Marie Bonnet, 1, 2,

More information

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging Dr. Olav E. Krigolson krigolson@uvic.ca Lecture 5: PARKINSONS DISEASE The Basal Ganglia Primary motor cortex Execution of movement

More information

Motor Fluctuations in Parkinson s Disease

Motor Fluctuations in Parkinson s Disease Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations

More information

L ecografia cerebrale: accuratezza diagnostica Dr Patrizio Prati Neurologia CIDIMU Torino

L ecografia cerebrale: accuratezza diagnostica Dr Patrizio Prati Neurologia CIDIMU Torino L ecografia cerebrale: accuratezza diagnostica Dr Patrizio Prati Neurologia CIDIMU Torino Ecografia cerebrale: l accuratezza diagnostica. Lo studio NOBIS Dr Patrizio Prati Neurologia CIDIMU Torinorin Normal

More information

Correspondence should be addressed to Peter Valkovic;

Correspondence should be addressed to Peter Valkovic; ISRN Neurology, Article ID 587302, 4 pages http://dx.doi.org/10.1155/2014/587302 Research Article Nonmotor Symptoms in Early- and Advanced-Stage Parkinson s Disease Patients on Dopaminergic Therapy: How

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/20183 holds various files of this Leiden University dissertation. Author: Rooden, Stephanie Maria van Title: Clinical patterns in Parkinson s disease Date:

More information

Nature, prevalence and clinical significance. Barcelona, Spain

Nature, prevalence and clinical significance. Barcelona, Spain Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated

More information

Use of the Pill Questionnaire to detect cognitive deficits and assess their impact on daily life in patients with Parkinson s disease

Use of the Pill Questionnaire to detect cognitive deficits and assess their impact on daily life in patients with Parkinson s disease Neurology Asia 2013; 18(4) : 369 375 Use of the Pill Questionnaire to detect cognitive deficits and assess their impact on daily life in patients with Parkinson s disease 1 Ji Seon Kim MD, 2 Jong-Min Kim

More information

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize

More information

Factors related to Caregiver Burden in Caregivers of Patients with Parkinson s disease in Mumbai, India.

Factors related to Caregiver Burden in Caregivers of Patients with Parkinson s disease in Mumbai, India. The International Journal of Indian Psychology ISSN 2348-5396 Volume 2, Issue 1, Paper ID: B00231V2I12014 http://www.ijip.in Oct to Dec 2014 Factors related to Caregiver Burden in Caregivers of Patients

More information

Parkinsonian Disorders with Dementia

Parkinsonian Disorders with Dementia Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University

More information

Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.

Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. UvA-DARE (Digital Academic Repository) Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. Link to publication Citation for published version (APA): Post, B. (2009). Clinimetrics,

More information

Health-Related Quality of Life in Early Parkinson s Disease: The Impact of Nonmotor Symptoms

Health-Related Quality of Life in Early Parkinson s Disease: The Impact of Nonmotor Symptoms RESEARCH ARTICLE Health-Related Quality of Life in Early Parkinson s Disease: The Impact of Nonmotor Symptoms Gordon W. Duncan, MBChB, MRCP, 1 * Tien K. Khoo, PhD, MRCP, 2 Alison J. Yarnall, MBBS, MRCP,

More information

Associated and predictive factors of depressive symptoms in patients with Parkinson s disease

Associated and predictive factors of depressive symptoms in patients with Parkinson s disease J Neurol (2016) 263:1215 1225 DOI 10.1007/s00415-016-8130-3 ORIGINAL COMMUNICATION Associated and predictive factors of depressive symptoms in patients with Parkinson s disease Kangdi Zhu 1 Jacobus J.

More information

SCOPA-AUT. 1. In the past month, have you had difficulty swallowing or have you choked?

SCOPA-AUT. 1. In the past month, have you had difficulty swallowing or have you choked? SCOPA-AUT By means of this questionnaire, we would like to find out to what extent in the past month you have had problems with various bodily functions, such as difficulty passing urine, or excessive

More information

The non-motor symptoms of Parkinson s disease of different motor types in early stage

The non-motor symptoms of Parkinson s disease of different motor types in early stage European Review for Medical and Pharmacological Sciences 2017; 21: 5745-5750 The non-motor symptoms of Parkinson s disease of different motor types in early stage L.-L. ZHONG 1,3, Y.-Q. SONG 2, H. CAO

More information

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A

More information

Psychiatric aspects of Parkinson s disease an update

Psychiatric aspects of Parkinson s disease an update Psychiatric aspects of Parkinson s disease an update Dr Chris Collins 027 2787593 chris.collins@cdhb.health.nz Disclosures: none Non-motor aspects physical Sensory anosmia, visual symptoms Speech and

More information

Parkinson s disease stakeholder workshop notes

Parkinson s disease stakeholder workshop notes Parkinson s disease stakeholder workshop notes Discussion on the scope relates to version 5.3 which was circulated at the stakeholder workshop. Group 1 o What aspects of the previous guideline would you

More information

THE IMPACT AND DETECTION OF NON-MOTOR SYMPTOMS IN PARKINSON S DISEASE

THE IMPACT AND DETECTION OF NON-MOTOR SYMPTOMS IN PARKINSON S DISEASE THE IMPACT AND DETECTION OF NON-MOTOR SYMPTOMS IN PARKINSON S DISEASE Janis Miyasaki, MD, MEd, FRCPC, FAAN University of Alberta Edmonton, Alberta, CANADA In the end of the twentieth century, neurology

More information

UPDATE ON RESEARCH IN PARKINSON S DISEASE

UPDATE ON RESEARCH IN PARKINSON S DISEASE UPDATE ON RESEARCH IN PARKINSON S DISEASE Charles H. Adler, M.D., Ph.D. Professor of Neurology Mayo Clinic College of Medicine Co-Principal Investigator Arizona Parkinson s Disease Consortium Arizona Study

More information

Burden of non-motor symptoms of Parkinson s disease

Burden of non-motor symptoms of Parkinson s disease SOLV0138 CDS handbook_text.qxd:cds handbook 1.3 8/10/07 16:30 Page 76 Burden of non-motor symptoms of Parkinson s disease Mary G Baker and Jill GC Rasmussen Introduction and background In an overview of

More information

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

TRANSPARENCY COMMITTEE OPINION. 18 March 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease

Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease For the attention of accredited medical writers only Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease Detailed

More information

Multiple System Atrophy

Multiple System Atrophy Multiple System Atrophy This document has been prepared to help you become more informed about Multiple System Atrophy. It is designed to answer questions about the condition and includes suggestions on

More information

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz Parkinson s Disease A Guide to Medical Treatment SEEd srl. All rights reserved Piazza Carlo Emanuele II, 19 10123 Torino, Italy Tel. 011.566.02.58

More information

King s Research Portal

King s Research Portal King s Research Portal DOI: 10.17925/ENR.2009.04.02.29 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version

More information

Comprehensive Approach to DLB Management

Comprehensive Approach to DLB Management Comprehensive Approach to DLB Management Bradley F. Boeve, MD Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Comprehensive Approach to DLB Management Disclosures

More information

Parkinson s disease (PD) is a progressive, disabling

Parkinson s disease (PD) is a progressive, disabling n reports n The Impact and Management of Nonmotor Symptoms of Parkinson s Disease Kelly E. Lyons, PhD and Rajesh Pahwa, MD Abstract Parkinson s disease (PD) is a common neurodegenerative disorder diagnosed

More information

Continuous dopaminergic stimulation

Continuous dopaminergic stimulation Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa

More information

Fatigue, mood disorders and sleep problems in patients with Parkinson's disease Havlikova, Eva

Fatigue, mood disorders and sleep problems in patients with Parkinson's disease Havlikova, Eva University of Groningen Fatigue, mood disorders and sleep problems in patients with Parkinson's disease Havlikova, Eva IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)

More information

Quality of Life Assessment in Atypical Parkinsonian Disorders

Quality of Life Assessment in Atypical Parkinsonian Disorders Quality of Life in Atypical Parkinsonian Disorders 277 17 Quality of Life Assessment in Atypical Parkinsonian Disorders Anette Schrag and Caroline E. Selai INTRODUCTION The atypical parkinsonian disorders

More information